title: Development of Churg-Strauss syndrome with controlled asthma during omalizumab treatment.
authors.forename: Anne-Marie
authors.initials: AM
authors.lastname: Ruppert
authors.forename: Gerlinde
authors.initials: G
authors.lastname: Averous
authors.forename: Daniela
authors.initials: D
authors.lastname: Stanciu
authors.forename: Nicolas
authors.initials: N
authors.lastname: Deroide
authors.forename: Sophie
authors.initials: S
authors.lastname: Riehm
authors.forename: Vincent
authors.initials: V
authors.lastname: Poindron
authors.forename: Gabrielle
authors.initials: G
authors.lastname: Pauli
authors.forename: Christian
authors.initials: C
authors.lastname: Debry
authors.forename: Frédéric
authors.initials: F
authors.lastname: de Blay
mesh_terms: D018927:Anti-Asthmatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy*; D015267:Churg-Strauss Syndrome / Q000209:etiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D000069444:Omalizumab
chemical_list: D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab